REG - Hutchmed China Ltd - 2024 Annual Report and Notice of AGM

HUTCHMED (China)Announcement

07/04/2025 09:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250407:nRSG7591Da&default-theme=true

RNS Number : 7591D  Hutchmed (China) Limited  07 April 2025

 

 

2024 Annual Report and Notice of Annual General Meeting

 

Hong Kong, Shanghai, & Florham Park, NJ - Monday, April 7, 2025: HUTCHMED
(China) Limited ("HUTCHMED (https://www.hutch-med.com/) ") (Nasdaq/AIM: HCM;
HKEX: 13) today announces that its 2024 Annual Report, together with the
Notice of Annual General Meeting and the Form of Proxy ("AGM Materials"), will
be posted on April 8, 2025 to those shareholders who have elected to receive
the AGM Materials in printed form. The documents can also be accessed from the
HUTCHMED website (www.hutch-med.com (https://www.hutch-med.com/) ).

 

The 2025 Annual General Meeting ("AGM") will be an electronic/hybrid meeting
to be held at 1st Floor, Harbour Grand Kowloon, 20 Tak Fung Street, Hung Hom,
Kowloon, Hong Kong on Tuesday, May 13, 2025 at 4:00 pm Hong Kong Time (9:00 am
London Time), with online access through an online platform as detailed in the
AGM Materials.

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery, global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. Since inception,
HUTCHMED has focused on bringing drug candidates from in-house discovery to
patients around the world, with its first three medicines marketed in China,
the first of which is also approved in the US, Europe and Japan. For more
information, please visit: www.hutch‑med.com (https://www.hutch-med.com/) or
follow us on LinkedIn (https://www.linkedin.com/company/hutchmed/) .

 

CONTACTS
 Investor Enquiries                                   +852 2121 8200 / ir@hutch-med.com (mailto:ir@hutch-med.com)

 Media Enquiries
 FTI Consulting -                                     +44 20 3727 1030 / HUTCHMED@fticonsulting.com
                                                      (mailto:HUTCHMED@fticonsulting.com)
    Ben Atwell / Alex Shaw                               +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
 Brunswick - Zhou Yi                                  +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                      (mailto:HUTCHMED@brunswickgroup.com)

 Panmure Liberum                                      Nominated Advisor and Joint Broker
 Atholl Tweedie / Freddy Crossley / Rupert Dearden    +44 20 7886 2500

 HSBC                                                 Joint Broker
 Simon Alexander / Alina Vaskina / Arnav Kapoor       +44 20 7991 8888

 Cavendish                                            Joint Broker
 Geoff Nash / Nigel Birks                             +44 20 7220 0500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAFLFIFSRISIIE